Peripheral prostaglandin metabolite levels in women undergoing therapeutic abortions in the first trimester with and without treatment with prostaglandin synthetase inhibitor

W. M. Wolfe, Ch V. Rao, E. M. McCracken, L. M. Demers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The levels of 11-deoxy-13,14-dihydro-15-keto-11β,16ζ-cyclo prostaglandin E2 (bicyclo PGEM), 13,14-dihydro-15 keto-prostaglandin F (PGFM) and prolactin were measured in four serial plasma samples collected from thirty women undergoing therapeutic abortions in the first trimester by a suction curettage procedure. Eleven of these women received a preoperative loading dose of sodium meclofenamate, a PG synthetase inhibitor, before the abortion procedure was started and the rest received this medication after the last blood samples were drawn. Prolactin levels increased significantly during the procedure. Sodium meclofenamate treatment had no effect on this increase. Bicyclo PGFM levels did not increase during the procedure in untreated or treated women, whereas PGFM levels increased but only in untreated women. The lack of increase in treated women apparently was not a treatment effect because PGFM levels in corresponding samples of untreated and treated women were similar. Treatment significantly reduced the bicyclo PGEM levels immediately after completion of the procedure as compared to untreated women. This differential PG response to treatment is unprecedented and may be due to sodium meclofenamate inhibition of PGE2 and not PGF synthesis. Nevertheless, these data demonstrate that sodium meclofenamate treatment of patients undergoing first trimester therapeutic abortion to relieve pain involves selective suppression of PGE2 synthesis.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalProstaglandins, Leukotrienes and Medicine
Volume28
Issue number1
DOIs
StatePublished - Jun 1987

Fingerprint

Meclofenamic Acid
Therapeutic Abortion
Prostaglandin Antagonists
First Pregnancy Trimester
Prostaglandin-Endoperoxide Synthases
Metabolites
Prostaglandins
Dinoprostone
Dinoprost
Prolactin
Therapeutics
Ligases
Vacuum Curettage
Blood
Plasmas
15-keto-13,14-dihydroprostaglandin F2alpha
Pain
11-deoxy-15-keto-13,14-dihydro-11 beta,16-cycloprostaglandin E2

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology
  • Endocrinology

Cite this

@article{63d46b3a85cc4eb2a2ccfd18b49dff60,
title = "Peripheral prostaglandin metabolite levels in women undergoing therapeutic abortions in the first trimester with and without treatment with prostaglandin synthetase inhibitor",
abstract = "The levels of 11-deoxy-13,14-dihydro-15-keto-11β,16ζ-cyclo prostaglandin E2 (bicyclo PGEM), 13,14-dihydro-15 keto-prostaglandin F2α (PGFM) and prolactin were measured in four serial plasma samples collected from thirty women undergoing therapeutic abortions in the first trimester by a suction curettage procedure. Eleven of these women received a preoperative loading dose of sodium meclofenamate, a PG synthetase inhibitor, before the abortion procedure was started and the rest received this medication after the last blood samples were drawn. Prolactin levels increased significantly during the procedure. Sodium meclofenamate treatment had no effect on this increase. Bicyclo PGFM levels did not increase during the procedure in untreated or treated women, whereas PGFM levels increased but only in untreated women. The lack of increase in treated women apparently was not a treatment effect because PGFM levels in corresponding samples of untreated and treated women were similar. Treatment significantly reduced the bicyclo PGEM levels immediately after completion of the procedure as compared to untreated women. This differential PG response to treatment is unprecedented and may be due to sodium meclofenamate inhibition of PGE2 and not PGF2α synthesis. Nevertheless, these data demonstrate that sodium meclofenamate treatment of patients undergoing first trimester therapeutic abortion to relieve pain involves selective suppression of PGE2 synthesis.",
author = "Wolfe, {W. M.} and Rao, {Ch V.} and McCracken, {E. M.} and Demers, {L. M.}",
year = "1987",
month = "6",
doi = "10.1016/0262-1746(87)90047-3",
language = "English (US)",
volume = "28",
pages = "53--59",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "1",

}

Peripheral prostaglandin metabolite levels in women undergoing therapeutic abortions in the first trimester with and without treatment with prostaglandin synthetase inhibitor. / Wolfe, W. M.; Rao, Ch V.; McCracken, E. M.; Demers, L. M.

In: Prostaglandins, Leukotrienes and Medicine, Vol. 28, No. 1, 06.1987, p. 53-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peripheral prostaglandin metabolite levels in women undergoing therapeutic abortions in the first trimester with and without treatment with prostaglandin synthetase inhibitor

AU - Wolfe, W. M.

AU - Rao, Ch V.

AU - McCracken, E. M.

AU - Demers, L. M.

PY - 1987/6

Y1 - 1987/6

N2 - The levels of 11-deoxy-13,14-dihydro-15-keto-11β,16ζ-cyclo prostaglandin E2 (bicyclo PGEM), 13,14-dihydro-15 keto-prostaglandin F2α (PGFM) and prolactin were measured in four serial plasma samples collected from thirty women undergoing therapeutic abortions in the first trimester by a suction curettage procedure. Eleven of these women received a preoperative loading dose of sodium meclofenamate, a PG synthetase inhibitor, before the abortion procedure was started and the rest received this medication after the last blood samples were drawn. Prolactin levels increased significantly during the procedure. Sodium meclofenamate treatment had no effect on this increase. Bicyclo PGFM levels did not increase during the procedure in untreated or treated women, whereas PGFM levels increased but only in untreated women. The lack of increase in treated women apparently was not a treatment effect because PGFM levels in corresponding samples of untreated and treated women were similar. Treatment significantly reduced the bicyclo PGEM levels immediately after completion of the procedure as compared to untreated women. This differential PG response to treatment is unprecedented and may be due to sodium meclofenamate inhibition of PGE2 and not PGF2α synthesis. Nevertheless, these data demonstrate that sodium meclofenamate treatment of patients undergoing first trimester therapeutic abortion to relieve pain involves selective suppression of PGE2 synthesis.

AB - The levels of 11-deoxy-13,14-dihydro-15-keto-11β,16ζ-cyclo prostaglandin E2 (bicyclo PGEM), 13,14-dihydro-15 keto-prostaglandin F2α (PGFM) and prolactin were measured in four serial plasma samples collected from thirty women undergoing therapeutic abortions in the first trimester by a suction curettage procedure. Eleven of these women received a preoperative loading dose of sodium meclofenamate, a PG synthetase inhibitor, before the abortion procedure was started and the rest received this medication after the last blood samples were drawn. Prolactin levels increased significantly during the procedure. Sodium meclofenamate treatment had no effect on this increase. Bicyclo PGFM levels did not increase during the procedure in untreated or treated women, whereas PGFM levels increased but only in untreated women. The lack of increase in treated women apparently was not a treatment effect because PGFM levels in corresponding samples of untreated and treated women were similar. Treatment significantly reduced the bicyclo PGEM levels immediately after completion of the procedure as compared to untreated women. This differential PG response to treatment is unprecedented and may be due to sodium meclofenamate inhibition of PGE2 and not PGF2α synthesis. Nevertheless, these data demonstrate that sodium meclofenamate treatment of patients undergoing first trimester therapeutic abortion to relieve pain involves selective suppression of PGE2 synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0023183567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023183567&partnerID=8YFLogxK

U2 - 10.1016/0262-1746(87)90047-3

DO - 10.1016/0262-1746(87)90047-3

M3 - Article

C2 - 3112807

AN - SCOPUS:0023183567

VL - 28

SP - 53

EP - 59

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 1

ER -